Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

News Releases

  •   Email
  •   Print
  •   Share

  • In the largest clinical study to date of genetic abnormalities in pediatric brain tumors, researchers performed clinical testing on more than 200 tumor samples and found that a majority had genetic irregularities that could influence how the disease was diagnosed and/or treated with approved drugs or agents being evaluated in clinical trials.

Tags: ChildhoodCancer, Genomics

  • Patients with metastatic colorectal cancer may be able to lower the risk of the disease worsening, and improve their chances of survival, if they engage in moderate daily exercise, according to new research by investigators at Dana-Farber.

Tags: ColonCancer, Exercise

  • UMass Memorial Medical Center and Dana-Farber Cancer Institute have notified the Massachusetts Health Policy Commission that UMass Memorial Medical Center intends to become the first academic medical center to join the Dana-Farber Cancer Care Collaborative.

Tags: Partnerships

  • Kenneth C. Anderson, MD, director of the Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics at Dana-Farber, will serve as president of the American Society of Hematology for a year-long term through December 2017.

Tags: Appointments

  • A comprehensive analysis led by Dana-Farber researchers suggests the two main types of esophageal cancer differ markedly in their molecular characteristics and should be considered separate diseases.

Tags: Genomics

  • Scientists at Dana-Farber Cancer Institute say they have discovered a potential explanation for why brain and heart tissues in very young children are more sensitive to collateral damage from cancer treatment than older individuals.

Tags: ChildhoodCancer, ChildhoodCancerSurvivorship

  • A new Dana-Farber study suggests that ANGPT2 protein may serve a prognostic biomarker for response to checkpoint inhibitors. Patients with metastatic melanoma involved in the study with lower ANGPT2 protein levels saw far greater benefit from these immunotherapy agents.

Tags: Melanoma, Immunotherapy

  • The American Society for Clinical Oncology (ASCO) has chosen Monica Bertagnolli, MD, of Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC), to lead the prestigious cancer organization as its president in 2018.

Tags: Appointments

  • EMMC Cancer Care, located at the Lafayette Family Cancer Center, is the newest member of the Dana-Farber Cancer Care Collaborative. In addition, EMHS (of which EMMC is a member) is also becoming an affiliate of Dana-Farber, which will enable streamlined access to Dana-Farber in Boston for patients with highly complex cancers.

Tags: Partnerships

  • 51 physicians and surgeons affiliated with Dana-Farber have been named to Boston magazine's annual "Top Doctors" guide.

Tags: Honors

Showing 1-10 of 747 items